K

Kevin J. Harrington

Royal Marsden NHS Foundation Trust

ORCID: 0000-0002-6014-348X

Publishes on Head and Neck Cancer Studies, Virus-based gene therapy research, Cancer Immunotherapy and Biomarkers. 1.5k papers and 74.1k citations.

PubIndex Score96Top 4% · seniorHow it's scored

1.5kPublications

74.1kTotal Citations

First publication: 1959First senior author: 1986

Head and Neck Cancer Studies Virus-based gene therapy research Cancer Immunotherapy and Biomarkers CAR-T cell therapy research Cancer Research and Treatments

Top publicationsby citations

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Robert L. Ferris, Maura L. Gillison, George R. Blumenschein et al.|New England Journal of Medicine|2016

Cited by 5.1k

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Signe Friesland, Douglas R. Adkins et al.|The Lancet|2018

Cited by 1.7k

Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

Robert L. Ferris, Maura L. Gillison, George R. Blumenschein et al.|Oral Oncology|2018

Cited by 802

Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Nancy Y. Lee, Ezra E.W. Cohen, Robert L. Ferris et al.|The Lancet Oncology|2021

Cited by 618

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

Kevin J. Harrington, J. Guigay, Robert L. Ferris et al.|The Lancet Oncology|2017

Cited by 431